세계의 판코니 빈혈 치료제 시장 : 치료 유형별, 연령층별, 병기별, 지역별
Fanconi Anemia Drug Market, By Treatment Type, By Age Group, By Disease Stage, By Geography
상품코드
:
1741179
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 판코니 빈혈 치료제 시장은 2025년 6억 3,410만 달러로 추정되고, 2032년까지 8억 9,820만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 5.1%를 보일 것으로 예측됩니다.
| 보고 범위 |
보고서 세부정보 |
| 기준연도 |
2024년 |
2025년 시장 규모 |
6억 3,410만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간: 2025-2032년 CAGR: |
5.10% |
2032년 가치 예측 |
8억 9,820만 달러 |
판코니 빈혈 치료제는 골수 부전, 선천성 결손, 암 발병 위험의 상승을 특징으로 하는 드문 유전성 질환인 판코니 빈혈의 증상이나 근본적인 유전자 이상을 치료하는 것을 목적으로 창조된, 또는 현재 연구 개발 중인 의약품 치료제입니다.
시장 역학:
과학적 조사의 지속적인 진전과 분자 메커니즘에 대한 지식이 예측 기간 동안 판코니 빈혈 치료제 시장의 성장을 견인할 것으로 예측됩니다. 질환 수식 치료의 개발은 예측 기간중, 세계의 판코니 빈혈 치료제 시장에 새로운 기회를 가져올 것으로 보입니다. 2022년 5월 17일, Jasper Therapeutics, Inc.는 판코니 빈혈 치료에서 컨디셔닝 제로서의 JPS191 연구를 위해 스탠포드 대학 의과의 Center for Definitive and Curative Medicine(CDCM)의 스폰서 연구에서 최초의 환자의 투여를 발표했습니다. 이 계약에 근거해, 스탠포드 대학 의학부는 비동포 기증자에 의한 동종 이식을 필요로 하는 골수부전의 판코니 빈혈 환자를 대상으로, JSP191을 이용한 제1/2상 임상시험(NCT04784052)을 실시했습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 판코니 빈혈 치료제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계의 판코니 빈혈 치료제 시장의 주요 기업을 프로파일 하고 있습니다.
- 본 보고서로부터의 통찰은 마케팅 담당자나 기업의 경영진이, 장래의 제품 발매, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시하는 것을 가능하게 할 것입니다.
- 판코니 빈혈 치료제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 판코니 빈혈증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 과학 연구와 분자 메커니즘의 이해의 지속적인 발전
- 충족되지 않은 의료 요구
- 인정된 치료법의 부족
- 질환 수식 요법의 개발
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
제4장 세계의 판코니 빈혈 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측의 분석
- 경제에 미치는 영향
제5장 세계의 판코니 빈혈 치료제 시장 : 치료 유형별, 2020-2032년
- 조혈 성장 인자
- 유전자 치료
- 줄기세포 이식
- 기타 치료법
제6장 세계의 판코니 빈혈 치료제 시장 : 연령층별, 2020-2032년
제7장 세계의 판코니 빈혈 치료제 시장 : 병기별, 2020-2032년
제8장 세계의 판코니 빈혈 치료제 시장 : 지역별, 2020-2032년
- 북미
- 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- 아프리카
제9장 경쟁 구도
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc.(Kite Pharma, Inc.)
- Celgene Corporation(Juno Therapeutics)
- Spark Therapeutics
- UniQure NV
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc.
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
제10장 섹션
JHS
영문 목차
Fanconi Anemia Drug Market is estimated to be valued at USD 634.1 Mn in 2025 and is expected to reach USD 898.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 634.1 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
5.10% |
2032 Value Projection: |
USD 898.2 Mn |
The fanconi anemia drugs are pharmaceutical therapies and treatments that have been created or are currently being researched with the goal of treating the symptoms and underlying genetic abnormalities of fanconi anemia, a rare genetic disorder that is marked by bone marrow failure, congenital defects, and an increased risk of developing cancer. Numerous organ systems are impacted by fanconi anemia. Fanconi anemia results from a defective gene that harms cells, and prevents them from mending damaged DNA. It has an impact on practically all body organs. It is also known as aplastic anemia that is hereditary.
Market Dynamics:
Continuous advancements in scientific research and knowledge about molecular mechanisms are expected to drive the global fanconi anemia drug market growth over the forecast period. Substantial unmet medical need will also continue to fuel growth of the global fanconi anemia drug market over the forecast period. This element motivates efforts in research and development to find efficient therapeutics for the control and treatment of FA. Development of disease-modifying therapies will create new opportunities for the global fanconi anemia drug market over the forecast period. There are opportunities for the creation of disease-modifying medications that can deal with the genetic alterations and molecular mechanisms connected to FA. For instance, on May 17, 2022, Jasper Therapeutics, Inc., a biotechnology company, announced the dosing of the first patient in its sponsored research of the Center for Definitive and Curative Medicine (CDCM) at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia. In accordance with the sponsored research agreement, Stanford Medicine is conducting a Phase 1/2 clinical trial (NCT04784052) utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors.
Key features of the study:
- This report provides in-depth analysis of the global fanconi anemia drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fanconi anemia drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Foresee Pharmaceuticals Co., Ltd., Rocket Pharmaceuticals Inc., Amgen, Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), Celgene Corporation (Juno Therapeutics), Spark Therapeutics, UniQure N.V, Bluebird Bio, Inc., PTC Therapeutics, Orchard Therapeutics Limited, GlaxoSmithKline Plc., Aurora Biopharma, Inc., Pfizer, Inc. and Autolus Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global fanconi anemia drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fanconi anemia drug market
Detailed Segmentation:
- By Treatment Type:
- Hematopoietic Growth Factors
- Gene Therapy
- Stem Cell Transplantation
- Other Therapies
- By Age Group:
- Pediatric Patients
- Adult Patients
- By Disease Stage:
- Early-stage Disease
- Advanced-stage Disease
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Foresee Pharmaceuticals Co., Ltd.
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Celgene Corporation (Juno Therapeutics)
- Spark Therapeutics
- UniQure N.V
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc
- Aurora Biopharma, Inc.
- Pfizer, Inc.
- Autolus Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Fanconi Anemia Drug, By Treatment Type
- Market Fanconi Anemia Drug, By Age Group
- Market Fanconi Anemia Drug, By Disease Stage
- Market Fanconi Anemia Drug, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Continuous advancements in scientific research and understanding of the molecular mechanisms
- Substantial unmet medical need
- Lack of recognized therapies
- Development of Disease-Modifying Therapies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Fanconi Anemia Drug Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Fanconi Anemia Drug Market, By Treatment Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Hematopoietic Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Other Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
6. Global Fanconi Anemia Drug Market, By Age Group, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
7. Global Fanconi Anemia Drug Market, By Disease Stage, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
- Early-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Advanced-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
8. Global Fanconi Anemia Drug Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Foresee Pharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rocket Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Celgene Corporation (Juno Therapeutics)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- UniQure N.V
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bluebird Bio, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Orchard Therapeutics Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurora Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Autolus Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
관련자료
